LUMA Vision has raised $22m in Series A3 financing to fund the FDA clearance and commercialisation of Verafeye in the country.

The financiers included EQT Lifesciences, ABV Uni Fund, imec.xpand, Atlantic Bridge Growth Fund and Bayern Kapital. It builds on previous funding from the Irish Government’s Disruptive Technologies Innovation Fund and the European Union’s EIC Accelerator grants of $6m and $3m, respectively.

Verafeye is a four-dimensional (4D) cardiac imaging and navigation platform that uses a proprietary catheter sensor combined with advanced digital imaging and deep learning to provide real-time guidance during cardiac surgery. Thereby, eliminating the need for external systems such as X-ray or CT scan.

The use of artificial intelligence (AI) such as deep learning has been increasing in the medical device sector. GobalData forecasts the AI market to reach sales of $93bn in 2023, a 12% increase from 2022. Many companies have invested in using AI in cardiac imaging.

In June, GE HealthCare launched a cardiac magnetic resonance imaging (MRI) testing device that uses deep learning. The technology can scan up to 12 times faster than current approaches meaning lengthy exam times often associated with cardiac MRIs, the gold standard for evaluating cardiac function, may be reduced.

In June, North Carolina-based Core Sound Imaging announced plans to preview its AI cardiac workflow solutions. The technology allows a cardiologist to choose from a menu of AI vendors and selectively utilise these AI tools on one or all exams. The technology is being piloted at the Mount Sinai Health System for echocardiogram (ECG) viewing and reporting.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Other advancements in cardiac imaging include Hyperfine’s portable MRI system, which is being trialled in an observational system in children with neurological injuries. The FDA-cleared Swoop system can provide brain MRI capabilities at the point of care. In September, CorVista Health’s non-invasive medical device system with a coronary artery disease add-on option for detecting the presence of cardiac disease was cleared by the FDA.